Assembly Biosciences (ASMB) Assets Average (2011 - 2026)

Assembly Biosciences' Assets Average history runs 16 years deep, the most recent figure standing at $246.5 million for Q1 2026.

• On a quarterly basis, Assets Average rose 126.0% year-over-year to $246.5 million in Q1 2026; TTM through Mar 2026 was $246.5 million, a 126.0% increase from a year earlier, with the FY2025 full-year figure at $188.4 million, up 47.18% from the prior year.
• Assets Average fell to $246.5 million in Q1 2026 per ASMB's latest filing, from $248.8 million in the prior quarter.
• Across five years, Assets Average topped out at $248.8 million in Q4 2025 and bottomed at $59.1 million in Q3 2023.
• The 5-year median for Assets Average is $111.7 million (2022), against an average of $130.2 million.
• Across the five-year window, Assets Average plunged 55.39% in 2023 and soared 126.76% in 2025, its largest moves.
• Year by year, Assets Average stood at $111.7 million in 2022, then fell by 15.61% to $94.2 million in 2023, then advanced by 16.44% to $109.7 million in 2024, then soared by 126.76% to $248.8 million in 2025, then slipped by 0.9% to $246.5 million in 2026.
• Per Business Quant, the three latest ASMB Assets Average figures stand at $246.5 million (Q1 2026), $248.8 million (Q4 2025), and $160.4 million (Q3 2025).